Docetaxel, carboplatin, and trastuzumab (TCH) preoperative induction treatment (IRx) in patients (pts) with HER2-positive breast cancer (BC).

e11065 Background: In randomised trials IRx consisting of chemotherapy (cRx) + H produced pathological complete responses (pCR, defined variously as absence of invasive cancer, or, absence of invasive and in-situ cancer) in 29-40% of pts with HER2+ BC. Most of the regimens which have been studied include an anthracycline (A), raising concerns about cardiac toxicity from H +A. Our unit adopted the non-A based TCH regimen which was developed by the BCIRG, as our standard for both IRx and adjuvant Rx of HER+BC in 2006, following the presentation of the data from the BCIRG 006 trial, in which TCH produced similar levels of activity to a more aggressive A+H containing regimen, but with substantially less cardiac toxicity. In preparation for a random assignment trial in which TCH will be compared to TC+/- Lapatinib (L) +/- H we studied the efficacy of the TCH regimen in producing pCR. Methods: We reviewed the records of all patients that received IRx TCH. The TCH regimen consisted of T 75mg/m2, C AUC 6 and H 6m...